相关实验视频

Updated: Jun 14, 2025

Retinal Pathophysiological Evaluation in a Rat Model

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

大麻素受体2的激动性在与糖尿病视网膜病变相关的实验模型中显示出治疗潜力

Cayla D Ontko¹, Taylor E Smith², Amy K Stark³

¹Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.

|June 12, 2025

概括

大麻素受体2 (CB2) 激动剂HU-308和CB65在糖尿病视网膜病变 (DR) 模型中有效降低了炎症和白细胞粘附. 这表明CB2激动症是早期DR的有希望的治疗策略,有可能预防视力丧失.

科学领域:

眼科医生眼科眼科
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

糖尿病视网膜病变 (DR) 的特征是视网膜血管炎症.
炎症性细胞因子TNFα和IL-1β有助于DR进展和白血静止.
大麻素受体2 (CB2) 激动体显示出治疗非核炎症状况的潜力.

研究的目的:

评估CB2激动剂 (HU-308,CB65) 在糖尿病视网膜病变模型中减轻白细胞粘附和炎症的疗效.
研究CB2激素的治疗潜力,用于早期的DR治疗.

主要方法:

使用暴露于炎症刺激的人类视网膜微血管内皮细胞 (hRMEC) 的体外研究.
在体内研究使用DR的小鼠模型.
评估了粘附分子的基因和蛋白质表达 (ICAM1,VCAM1,SELE).
测量白细胞粘附和核因子 κB (NF-κB) 转位.

主要成果:

HU-308和CB65显著降低了hRMEC中的粘附分子的炎症基因和蛋白质表达.
CB2激动剂抑制了白细胞对hRMEC单层的粘附.
HU-308和CB65降低了NF-κB的转移和激活.
在体内,HU-308的使用在DR模型中降低了视网膜白血静止.

结论:

在糖尿病视网膜病变中,CB2激进作用有效地减轻了关键的炎症过程.
CB2激动剂在DR中表现出对控制视网膜白细胞静止的治疗潜力.
准CB2受体提供了一个合理的方法,用于早期DR的临床应用.

更多相关视频

Characterization of a Novel Human Organotypic Retinal Culture Technique

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

G Protein-coupled Receptors

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...